/* ========================================================= BlogPosts2.jsx — Sprint 4 product deep-dive bodies Loaded AFTER Blog.jsx; extends window.BLOG_BODIES. ========================================================= */ (function () { const { BlogH2, BlogH3, BlogP, BlogPull, BlogUL, BlogTable, BlogCallout } = window; const goLink = (route, slug) => (e) => { e.preventDefault(); window.__go && window.__go(route, slug); }; /* ---------- BPC-157 ---------- */ function BPC157Body() { return ( <> BPC-157 — Body Protection Compound 157 — is a synthetic pentadecapeptide derived from a 62-amino-acid protein originally isolated from human gastric juice. It is 15 residues long, has no cysteine, no known receptor, and a research footprint that runs to several hundred preclinical papers. It is also the single most over-marketed peptide in the consumer-facing research supply market. This review attempts to separate what has been shown in animal and cell-culture models from what has been extrapolated, assumed, or invented. It is not a therapeutic endorsement; it is a reading of the literature. Structure and origin The sequence is GEPPPGKPADDAGLV. It corresponds to residues 146–160 of a protective protein present in gastric juice, first characterized by Sikirić and colleagues at the University of Zagreb in the early 1990s. The Zagreb group has since published the majority of the preclinical work on the peptide — a fact that is worth naming, because the literature is unusually concentrated in a single research lineage. Proposed mechanisms BPC-157 does not bind a known receptor with high affinity. The mechanisms proposed in the literature are downstream — measured changes in signaling cascades and gene expression rather than direct agonism. Angiogenesis & VEGFR2 Multiple studies report upregulation of vascular endothelial growth factor receptor 2 (VEGFR2) in response to BPC-157 exposure, with downstream activation of the VEGFR2-Akt-eNOS pathway. In rodent tendon-injury and muscle-crush models, this correlates with accelerated capillary ingrowth at the injury site. The effect is consistent across labs but mechanistically incomplete — the proximal step (how the peptide reaches VEGFR2) is not resolved. Nitric oxide system Several papers describe BPC-157 as stabilizing the nitric oxide system in models of ischemic injury. Coadministration with L-NAME (an NOS inhibitor) attenuates the protective effect; coadministration with L-arginine restores it. This is suggestive of NO-mediated signaling but does not identify a specific target. Growth hormone receptor expression A 2018 paper from the Zagreb group reported upregulation of the growth hormone receptor in tendon fibroblasts exposed to BPC-157 in vitro. This is the most-cited proposed mechanism for the peptide's reputation as a "tendon-healing" compound, though the in vivo extrapolation rests on a single lineage of studies. The consistent story across the literature is not a receptor — it is a collection of downstream effects, measured in injured tissue, that accelerate a normal repair cascade. How the peptide triggers that cascade remains unresolved. Preclinical findings The animal-model literature is broad but methodologically uneven. Categorized: A reasonable read of this table is that BPC-157 has consistent, replicated effects on GI mucosal healing and musculoskeletal injury in rodents. The neurological literature is earlier-stage and should not be overstated. Human data There are no published randomized controlled trials of BPC-157 in humans. There are no completed Phase 1 safety studies in the public literature. A small number of open-label or observational reports exist in non-peer-reviewed venues, but none meet the evidence standard that would support clinical recommendations. The gap between the preclinical literature and human evidence is the single most important fact about BPC-157. A compound that looks promising in 40 rodent studies is exactly the kind of compound that may — or may not — translate to a safe and effective human therapy. Without Phase 1 data, that question is open. Pharmacokinetics Published PK data on BPC-157 is sparse. The peptide has been described as orally active in rodent models, which is unusual for a 15-residue peptide and has not been reconciled with conventional peptide-pharmacology expectations (oral bioavailability for unmodified peptides of this size is typically {'<'} 2%). Half-life after parenteral administration in rodents is reported in the 4–6 hour range; human PK has not been characterized. What a researcher actually receives BPC-157 is supplied as a white lyophilized powder, typically as the acetate salt. The relevant analytical specifications on a credible COA:

HPLC purity ≥ 99.0%, with full chromatogram.

Identity by ESI-MS matching 1419.5 ± 1 Da.

Net peptide content by AAA ≥ 85%.

Water content (Karl Fischer) ≤ 6%.

Acetate content 6–10% (for acetate salt).

Sterility and endotoxin (LAL) for injectable-research-grade material.

For background on reading these numbers, see How to read a peptide COA and HPLC purity vs peptide content.

BPC-157 vs TB-500 — the two repair-axis peptides, compared.

BPC-157 product spec sheet — Clarion lot specifications.

Peptide storage guide — BPC-157 is stable when lyophilized; reconstituted material requires cold storage.

Research use only. Clarion Peptides supplies BPC-157 for laboratory research. It is not a drug, dietary supplement, or approved therapy. Not for human or veterinary use. ); } /* ---------- Tirzepatide ---------- */ function TirzepatideBody() { return ( <> Tirzepatide is the first clinically-approved dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It is a 39-residue synthetic peptide with a C20 fatty diacid moiety attached to Lys20 via a linker — the lipid anchor that enables weekly dosing. Developed by Eli Lilly, marketed as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management), and tested across the SURPASS and SURMOUNT trial programs, tirzepatide is the most rigorously characterized peptide in the current research supply market. This review summarizes the pharmacology from the published primary literature. Structure The lipid modification is the central pharmacokinetic engineering choice. The C20 diacid binds circulating albumin non-covalently, creating a depot that slows renal clearance. Semaglutide uses a similar strategy with a C18 diacid; the longer chain in tirzepatide contributes to its somewhat longer half-life. Receptor pharmacology Tirzepatide activates both the GIP and GLP-1 receptors, but not symmetrically. Published in-vitro receptor-binding and cAMP-accumulation data show: The GLP-1R bias is notable. Tirzepatide couples GLP-1R activation more strongly to cAMP generation than to β-arrestin recruitment. β-arrestin recruitment drives receptor internalization, which is a tachyphylaxis mechanism. The reduced internalization may contribute to sustained signaling and, speculatively, to the tolerability profile at higher doses. The two receptors contribute different physiology. GLP-1 activation drives glucose-dependent insulin secretion and satiety; GIP activation contributes to adipose handling and may modulate nausea. The dual agonism is not additive — it is combinatorial. The SURPASS and SURMOUNT programs Tirzepatide entered the clinic with one of the most comprehensive incretin-class trial programs on record. The SURPASS 1–5 trials assessed glycemic control in type 2 diabetes; SURMOUNT 1–4 assessed body-weight effects in non-diabetic obesity. A compressed summary of published findings: The SURMOUNT-1 weight-loss magnitude was, at publication, the largest observed in a Phase 3 pharmacotherapy trial for obesity and resets the reference range against which subsequent dual and triple agonists are measured. How it differs from semaglutide The head-to-head pharmacology is covered in detail in the semaglutide vs tirzepatide comparison. Briefly:

Semaglutide is a selective GLP-1R agonist; tirzepatide adds GIPR activation.

Semaglutide has an ≈ 7-day half-life; tirzepatide ≈ 5 days — both support weekly dosing.

Head-to-head (SURPASS-2) showed tirzepatide superior on HbA1c and weight at all approved doses.

GI adverse-event profiles are broadly similar; the GIP contribution to nausea handling remains under investigation.

Research-grade supply considerations Tirzepatide is a difficult peptide to synthesize. At 39 residues with a lipidated lysine, the synthesis requires careful orthogonal protection of the Lys20 ε-amine, off-resin lipid conjugation, and a final HPLC purification capable of resolving closely related truncation and diastereomer impurities. A credible research-grade lot should specify:

HPLC purity ≥ 99.0%, with full chromatogram and individual impurity profile.

Identity by ESI-MS matching 4813.5 ± 2 Da.

Net peptide content ≥ 85% by AAA.

Lipid-conjugation confirmation by MS/MS fragment analysis.

Sterility + endotoxin for injectable research grade.

Counterfeits and under-purified material are common at this complexity level. See red flags on a peptide COA for vetting guidance.

Semaglutide vs tirzepatide — receptor pharmacology and trial outcomes, side-by-side.

Tirzepatide product spec sheet — Clarion lot specifications.

How to vet a peptide supplier — what to verify before you order a complex lipidated peptide.

Research use only. Clarion Peptides supplies tirzepatide for laboratory research. It is not supplied as, or intended to substitute for, the branded products Mounjaro® or Zepbound®, which are prescription medicines regulated by the FDA. ); } /* ---------- GHK-Cu ---------- */ function GHKCuBody() { return ( <> GHK-Cu — glycyl-L-histidyl-L-lysine complexed with copper(II) — is a three-amino-acid peptide with a research footprint that is vastly disproportionate to its size. It was first isolated from human plasma in 1973 by Pickart and colleagues, who noticed that serum from young donors promoted liver cell growth more effectively than serum from older donors, and traced the activity to a small copper-binding fragment. Five decades of subsequent research have characterized GHK-Cu as a gene-modulating compound with effects on skin remodeling, hair follicle biology, and wound healing. It is also one of the few peptides where the copper is not incidental — the metal is part of the pharmacophore. Structure The copper is coordinated by the histidine imidazole nitrogen, the α-amine of glycine, and the deprotonated amide nitrogen between glycine and histidine. This geometry is thermodynamically favorable — GHK has an unusually high binding constant for Cu(II) — and the complex is physiologically stable at serum pH. Why the copper matters Most of the biological activity attributed to GHK-Cu requires the copper. The free peptide has weaker effects in parallel assays. Three reasons the metal is central:

Superoxide dismutase mimicry. The Cu(II) center can accept and donate electrons, giving GHK-Cu SOD-like activity that scavenges superoxide radicals.

Cofactor delivery. Copper is a required cofactor for lysyl oxidase (collagen cross-linking) and tyrosinase (melanin). GHK-Cu acts as a bioavailable copper shuttle.

Redox signaling. Transient copper redox cycling in the cellular microenvironment modulates signaling pathways including HIF-1α stabilization and NF-κB activity.

GHK-Cu is not really "a peptide with a metal attached." It is a copper-delivery system with a peptide scaffold that makes the metal biologically selective. Gene-expression effects A 2010 microarray study by Pickart and colleagues treated human fibroblasts with GHK-Cu and measured transcriptome-wide changes. Roughly 4,000 genes (≈15% of the transcriptome) showed significant altered expression. The top-enriched pathways included tissue remodeling, antioxidant response, DNA repair, and apoptotic signaling. This broad gene-expression modulation is both GHK-Cu's most cited feature and its most frequently over-interpreted one. A pleiotropic effect in cell culture does not translate directly to a therapeutic effect in a whole organism, and the downstream phenotypic evidence is less voluminous than the transcriptomic data would suggest. Reported tissue-level effects Clinical use GHK-Cu has a notable presence in the topical cosmetic market, where it is formulated into serums and wound-healing creams. Clinical data supporting these applications is limited but not absent: small controlled trials have reported improvements in skin thickness, elasticity, and clinical photoaging scores with 12-week topical use. The evidence base for injectable research-grade GHK-Cu in humans is thinner. Research handling GHK-Cu is supplied as a deep blue lyophilized powder — the color comes from the copper-peptide charge-transfer absorbance around 520 nm. Handling considerations:

Light-sensitive when in solution; store reconstituted stocks in amber or foil-wrapped vials.

pH-sensitive; the Cu(II) complex is most stable between pH 6.5–8.0.

Incompatible with high concentrations of chelators (EDTA, phosphate) that strip the copper.

Typical research acceptance spec: HPLC purity ≥ 98%, Cu content by ICP-MS within 5% of theoretical.

GHK-Cu product spec sheet — Clarion lot specifications including ICP-MS copper verification.

Peptide storage guide — GHK-Cu light and pH sensitivity.

How to read a peptide COA — what to look for on a metal-complexed peptide COA.

Research use only. Clarion Peptides supplies GHK-Cu for laboratory research. Not for human or veterinary use. ); } /* ---------- BPC-157 vs TB-500 ---------- */ function BPCvsTB500Body() { return ( <> BPC-157 and TB-500 are the two peptides most frequently described as "healing" or "recovery" compounds in research-supply catalogs. They are frequently stacked, frequently confused, and almost never described with any precision. They are genuinely different molecules with different mechanisms, different pharmacokinetic profiles, and different weights of supporting evidence. At a glance Mechanistic contrast The most common misreading is that these peptides "do the same thing." They do not. BPC-157: extracellular angiogenesis signaling BPC-157's proposed effects are mediated through extracellular signaling pathways — VEGFR2 upregulation, nitric oxide system stabilization, growth hormone receptor expression in fibroblasts. The downstream consequence is accelerated vascularization of injured tissue. See the BPC-157 research review for detail. TB-500: intracellular actin dynamics Thymosin β4 is a 43-residue intracellular protein whose primary function is sequestering monomeric (G-) actin, regulating the pool available for cytoskeletal polymerization. The "TB-500" sold in research-supply catalogs is most commonly a synthetic fragment — sometimes the full Tβ4 sequence, sometimes a shorter active region (notably Ac-SDKP, the N-terminal tetrapeptide). Extracellular Tβ4 and its cleavage fragments additionally promote endothelial cell migration and angiogenesis, but the headline activity is intracellular cytoskeletal modulation. BPC-157 is a receptor-signaling story. TB-500 is a cytoskeletal-dynamics story. The fact that both modulate tissue repair does not mean they do so by parallel mechanisms. Evidence bases A fair reading: BPC-157 has more rodent-model breadth but no human trials. Tβ4 (the parent of TB-500) has less preclinical breadth but genuine clinical-trial activity in specific indications. This is not a "which is better" question — it is a which-question-are-you-asking question. On the practice of stacking them Research-community lore frequently describes BPC-157 and TB-500 as synergistic in recovery protocols. The mechanistic rationale offered is that BPC-157 accelerates vascularization while TB-500 supports cellular migration into the vascularized bed. This is biologically plausible; it is not demonstrated in controlled studies. No published, peer-reviewed work — to our knowledge — has measured the combined effect in a rigorous head-to-head design. Claims of synergy between research peptides are among the most frequently overstated claims in the supply market. A biologically plausible combination is not the same as a tested combination. Practical differences for handling

BPC-157 research review — the literature in detail.

BPC-157 and TB-500 spec sheets.

BPC-157 + TB-500 research kit — for researchers who want matched lots of both.

Research use only. Clarion Peptides supplies BPC-157 and TB-500 for laboratory research. Not for human or veterinary use. ); } /* ---------- Semaglutide vs Tirzepatide ---------- */ function SemaVsTirzBody() { return ( <> Semaglutide and tirzepatide are the two most-prescribed peptide therapeutics in the world. They share a drug class (long-acting incretin analogs), a weekly dosing cadence, and a therapeutic footprint that spans type 2 diabetes and chronic weight management. They also differ in ways that matter: receptor selectivity, pharmacokinetics, synthesis difficulty, and — in head-to-head clinical trials — efficacy. This piece compares the two at the level a pharmacology-literate researcher would want. It is not a prescribing guide; it is a structural comparison of molecules and the evidence behind them. Receptor pharmacology The signaling-bias distinction is subtle but matters. β-arrestin recruitment at GLP-1R drives receptor internalization, which is one tachyphylaxis mechanism. Tirzepatide's reduced β-arrestin engagement at GLP-1R may contribute to sustained signaling at higher doses — though causal attribution from clinical outcomes back to this in-vitro property is speculative. Molecular structure Both peptides use the same lipid-anchor strategy for long half-life: a fatty diacid linked via γ-glutamic acid and polyethylene glycol spacers to a lysine sidechain. The albumin-binding affinity scales with the diacid chain length, which is part of why tirzepatide's chain (C20) gives a marginally longer tissue residence than semaglutide's (C18). The important difference is not the fatty-acid tail. It is what the backbone does when it arrives at the receptor — and tirzepatide arrives at two receptors. Pharmacokinetics Head-to-head clinical data SURPASS-2 (2021) is the most-cited head-to-head trial: tirzepatide (5, 10, 15 mg) vs semaglutide 1 mg, over 40 weeks, in adults with type 2 diabetes on metformin. Published outcomes: Tirzepatide was superior at every approved dose on both primary and secondary endpoints. SURPASS-2 is the basis for the frequent clinical characterization of tirzepatide as "the best-in-class incretin therapy" for glycemic control. For weight management (non-diabetic obesity), the equivalent head-to-head is forthcoming at time of writing; indirect comparisons of SURMOUNT-1 and STEP-1 suggest a similar ranking, with tirzepatide delivering larger weight reductions than semaglutide at matched dosing intervals. Tolerability Adverse-event profiles are broadly similar across the class. The dominant AEs are gastrointestinal — nausea, vomiting, diarrhea, constipation — and are dose- and titration-dependent. In head-to-head trials, the incidence of GI AEs was comparable between semaglutide and tirzepatide at matched glycemic efficacy, though the absolute numbers differ across trials because of different titration schedules. A speculative but widely-discussed hypothesis: the GIP component of tirzepatide may attenuate GLP-1-driven nausea. GIP receptors in hindbrain regions have been implicated in this effect in preclinical work. The in-vivo human evidence is suggestive but not conclusive. Research-supply considerations For supplier-vetting guidance on lipidated peptides specifically, see how to vet a peptide supplier.

Tirzepatide research review — the pharmacology in full.

Semaglutide and tirzepatide Clarion spec sheets.

COA red flags — lipidated peptides are the most-counterfeited class in the market.

Research use only. Clarion Peptides supplies semaglutide and tirzepatide for laboratory research. These are not substitutes for, and are not supplied as, the branded prescription medicines Ozempic®, Wegovy®, Mounjaro®, or Zepbound®. ); } /* ---- Register bodies ---- */ Object.assign(window.BLOG_BODIES, { 'bpc-157-research-review': BPC157Body, 'tirzepatide-research-review': TirzepatideBody, 'ghk-cu-research-review': GHKCuBody, 'bpc-157-vs-tb-500': BPCvsTB500Body, 'semaglutide-vs-tirzepatide': SemaVsTirzBody, }); })();